Dual-action nanoparticle therapy for osteoarthritis
Official title: Development of Dual-Action Nanoparticle-Loaded Microparticles for Osteoarthritis Treatment
Funded at University of Pennsylvania · NIH-11405011 · Data updated 2026-11-12
A patient-friendly look at a new treatment approach that combines two tiny drug-delivery systems to protect and repair damaged knee tissue in people with osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 5, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $612,052 |
| NIH project number | 5R01AR086381-02 |
| Project ID | NIH-11405011 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with osteoarthritis who are candidates for joint-directed therapies and potential participants in future clinical studies.
✕Less likely to help
Patients with OA who may not respond to nanoparticle-based approaches or who have contraindications to trial participation may not benefit.
What this research studies
This project uses two specially designed nanoparticles to deliver therapies directly into the joint: one type encourages cartilage repair, and the other reduces harmful inflammation and damage. The approach aims to stay in the joint longer, reducing how often medicines must be given and lowering the risk of side effects. Researchers will test these nanoparticles in models that mimic human joints to understand how well they work and how safe they are before moving toward people with OA. If successful, this could slow or halt cartilage deterioration and improve joint function for OA patients.
Why it matters
Potential benefit: If successful, the therapy could reduce pain and improve joint function by slowing cartilage degeneration in osteoarthritis.
How similar studies have gone: Previous nanoparticle approaches showed promise in preclinical models, but human effectiveness remains to be demonstrated.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Cheng, Zhiliang — University of Pennsylvania
- Study coordinator: Cheng, Zhiliang
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.